skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines

Frontiers in endocrinology (Lausanne), 2018-04, Vol.9, p.146-146 [Peer Reviewed Journal]

COPYRIGHT 2018 Frontiers Research Foundation ;Copyright © 2018 Exner, Prasad, Wiedenmann and Grötzinger. 2018 Exner, Prasad, Wiedenmann and Grötzinger ;ISSN: 1664-2392 ;EISSN: 1664-2392 ;DOI: 10.3389/fendo.2018.00146 ;PMID: 29681888

Full text available

Citations Cited by
  • Title:
    Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
  • Author: Exner, Samantha ; Prasad, Vikas ; Wiedenmann, Bertram ; Grötzinger, Carsten
  • Subjects: cell line ; Cell proliferation ; Dosage and administration ; Endocrinology ; neuroendocrine tumor ; octreotide ; radiation sensitivity ; Somatostatin ; somatostatin analog ; somatostatin receptor
  • Is Part Of: Frontiers in endocrinology (Lausanne), 2018-04, Vol.9, p.146-146
  • Description: Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated significant improvement of progression-free survival under SSA treatment. Furthermore, somatostatin receptor (SSTR) overexpression in NET has also been utilized for diagnostic imaging and peptide receptor radionuclide therapy (PRRT). However, PRRT in NET is associated mostly with partial and minor remission, while other radionuclide therapies reach complete remissions in up to 75% of cases. This study assessed a potential radiosensitizing effect of SSA treatment in five established NET cell line models: BON, QGP-1, LCC-18, H727, and UMC-11. Irradiation was found to significantly inhibit proliferation, while no additional effect by octreotide treatment was observed. Intriguingly, no impact of SSA treatment alone was found in any of these NET cell lines when systematically analyzing cell viability, proliferation, and cell cycle distribution. Investigation of the causes for this octreotide resistance led to demonstration of low octreotide binding and scarce SSTR, specifically SSTR2 expression as compared to levels found in human NETs. The resistance toward SSA treatment in viability and proliferation assays could not be overcome by re-expression of SSTR2 in two of the cell lines. These results provide systematic evidence for a lack of authentic, tumor-like SSTR expression, and function in five frequently used NET cell line models and point to the need for more physiologic tumor model systems.
  • Publisher: Switzerland: Frontiers Research Foundation
  • Language: English
  • Identifier: ISSN: 1664-2392
    EISSN: 1664-2392
    DOI: 10.3389/fendo.2018.00146
    PMID: 29681888
  • Source: GFMER Free Medical Journals
    PubMed Central
    ROAD: Directory of Open Access Scholarly Resources
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait